Literature DB >> 8719548

Immunosuppressive treatment of the glomerulonephritis of systemic lupus.

R Faedda1, D Palomba, A Satta, M Pirisi, F Tanda, E Bartoli.   

Abstract

To evaluate the results, the long-term prognosis and the rates of complication of an immunosuppressive regimen with corticosteroids and cyclophosphamide in the treatment of the nephritis of systemic lupus erythematosus, 21 patients with lupus glomerulonephritis were studied. Renal biopsies were performed in 17/21 of them and indicated diffuse proliferative (6 patients), diffuse mesangial (4) and membranous (7) glomerulonephritis. Treatment was structured in 4 phases: 1) induction with methylprednisolone 250 mg i.v. for 7-14 days, and cyclophosphamide 100-200 mg p.o., q.d., or 20 mg/kg i.v. every 28 days; 2) maintenance with prednisone p.o., 2 mg/kg q.o.d. for 45 days, and cyclophosphamide as before; 3) tapering, with reduction of prednisone by 15% each month for 4 months; 4) indefinite maintenance with prednisone slowly tapered to the least effective q.o.d. dose and cyclophosphamide discontinued after six months of treatment. This cycle was repeated in the event of a relapse. After a first immunosuppressive cycle, 20/21 patients achieved remission of glomerulonephritis. Plasma creatinine fell from 97 +/- 6 to 80 +/- 3 microMol/l (p < 0.01). Proteinuria fell from 2.1 +/- 0.4 to 0.2 +/- 0.4 g/d (p < 0.0001) and the nephrotic syndrome, present in 8 patients, disappeared. After an average of 20 +/- 7 months, 8 patients relapsed: all remitted again after a repeat cycle, but 1 later progressed to end-stage renal failure during pregnancy. After an average of 56 months 4 out of these 8 patients relapsed again: 1 progressed to end-stage renal disease following an abortion and 3 remitted completely after a third cycle. Thus, 18 out of 21 patients are presently in remission with an average dose of prednisone of 13.7 mg/day after an average follow-up of 52 +/- 38 months (range 2 to 156). Three patients are presently off treatment. In 16 patients with extended follow-up of 2 to 13 years, anti-nuclear antibodies, anti-DNA antibodies, albuminuria and cylindruria fell below post-cycle levels (p < 0.001 for all). We conclude that intensive immunosuppression with steroids and cyclophosphamide can achieve excellent long-term results in the treatment of systemic lupus with glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719548

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Immunosuppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide: factors associated with a favourable outcome.

Authors:  M Pirisi; R Faedda; A Satta; E Bartoli
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Julio C Sartori-Valinotti; Christine Maric; Lorraine C Racusen; Porter H Glover; Gerald R McLemore; Allison V Jones; Jane F Reckelhoff; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-04       Impact factor: 3.619

Review 3.  The value of repeat biopsy in lupus nephritis flares.

Authors:  Javier Narváez; Milagros Ricse; Montserrat Gomà; Francesca Mitjavila; Xavier Fulladosa; Olga Capdevila; Joan Torras; Xavier Juanola; Ramón Pujol-Farriols; Joan Miquel Nolla
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.